Idera to Present at the 35th Annual J.P. Morgan He

CAMBRIDGE, Mass. and EXTON, Pa., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA ), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that the company will present at the 35 ^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at 11:00 a.m. Pacific Time (2:00 p.m. Eastern Time) at the Westin St. Francis in San Francisco. Idera’s Chief Executive Officer, Vincent Milano, will present a corporate overview and provide an update on the company’s plans and expectations for 2017.

Live audio webcasts of Idera’s presentation and following Q&A session will be accessible in the Investors and Media section of Idera’s website at http://www.iderapharma.com .  An archived version will also be available on the Company’s website after the event for 90 days.  As a convenience to investors, a copy of the company’s presentation will be posted on the Idera corporate website at 8:00 a.m. Eastern Time on Monday, January 09, 2017.

About Idera Pharmaceuticals            Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Idera’s proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera has created a third generation antisense technology platform using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com .

Investor and Media Contact Robert Doody VP, IR & Corporate Communications 617-679-5515 (office) 484‐639‐7235 (mobile) rdoody@iderapharma.com